Chargement en cours...
KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin-or irinotecan-based treatment
Fluoropyrimidine-based chemotherapy plus antibody therapy is currently the standard first-line treatment for metastatic colorectal cancer (mCRC). In this study, we investigated the hypothesis that mutations in several of the targeted oncogenes are correlated with treatment outcomes in mCRC patients...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
D.A. Spandidos
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3999142/ https://ncbi.nlm.nih.gov/pubmed/24772300 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2014.254 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|